Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare ...
Foundational health behaviors reduce migraine burden, but frequent or disabling attacks commonly require preventive treatment ...
A new study suggests excessive daytime sleepiness in obstructive sleep apnea may be associated with cognitive impairment and ...
The FDA has approved UX111 (Fayuvi; Ultragenyx Pharmaceutical), an adeno-associated virus serotype 9 (AAV9) gene therapy, for the treatment of pediatric patients with Sanfilippo syndrome type A ...
"Unmet Needs and Mechanisms Behind Newer Agitation Therapies" takes up what still remains unmet in agitation care, and the biology behind a newer treatment option.
Levacetylleucine (AQNEURSA) is approved for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg, in addition to its existing indication for ...
HIMALAYA was a multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted at 63 sites across 13 ...
Ahead of Myotonic Dystrophy Awareness Day, here's a snapshot of 7 investigational agents currently in the DM1 pipeline (and, ...
The 2026 AHA/ASA adult stroke rehabilitation guideline updates the 2016 framework, addressing evidence-based recovery ...
The American Academy of Neurology (AAN) and American Headache Society (AHS) have issued an updated practice guideline on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results